Journal of Clinical Oncology
Articles in this Issue
Impact of BRCA alterations on androgen receptor pathway inhibition treatment outcome in advanced prostate cancer.
e17074 Background: Prostate cancer (PCa) is a heterogeneous disease at both molecular and clinical levels. Alterations in homologous recombination repair...
LRRC15-radioimmunotheranostics: Targeting TGFβ-driven resistance in immune-excluded solid tumors.
e15133 Background: Leucine-Rich Repeat-Containing Protein 15 (LRRC15), a TGFβ-regulated antigen, is prominently expressed...
A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).
TPS9613 Background: Uveal melanoma (UM) is a rare malignancy that develops from melanocytes in the eye. At least half of the patients develop metastases,...
Prognostic factors and treatment outcomes in stage IV endometrial carcinoma: A 13-year single center experience.
e17630 Background: Systemic therapy is the cornerstone of managing stage IV endometrial cancer (EC). Treatment has expanded beyond platinum-taxane chemoth...
Artificial Intelligence-based tumor microenvironment and PD-L1 analysis using digital pathology to predict pembrolizumab response in metastatic triple-negative breast cancer.
1110 Background: The combination of pembrolizumab and chemotherapy improves survival in programmed death ligand 1 (PD-L1) positive metastatic triple-negat...
Immune-related adverse events to predict outcomes in recurrent/metastatic cervical cancer treated with cemiplimab: Insights from a rescue access program in Poland.
e17504 Background: Recurrent/metastatic cervical cancer remains a significant clinical challenge, particularly after progression on platinum-based chemoth...
Central neck lymphadenectomy at surgical treatment of papillary thyroid cancer.
e18128 Background: Necessity of local forms of highly differentiated thyroid cancer preventative central neck lymphatic dissection is currently an open qu...
Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).
e17085 Background: Inactivating missense mutations in the tumor suppressor gene speckle-type POZ (SPOP) increase the transcriptional activity of the andro...
Outcomes in liver transplant recipients with and without obesity: A propensity-matched analysis using the TriNetX database.
e23096 Background: Obesity is a growing concern among liver transplant recipients and has been linked to adverse post-transplant outcomes. This study aims...
Low-dose albumin-bound paclitaxel and enhancement of anti-PD-1 therapy in bladder cancer by shaping the inflammatory immune microenvironment through induction of mitochondrial stress: Results from the phase 2 TRUCE-01 and TRUCE-02 trails.
e16597 Background: Our previous studies demonstrated that low-dose albumin-bound paclitaxel combined with toripalimab achieved a complete clinical respons...
Anti-tumor activity of BH-30643, a novel macrocyclic kinase inhibitor, in <i>EGFR</i> -mutant lung cancer models.
3110 Background: Outcomes on tyrosine kinase inhibitor (TKI) treatment in EGFR -mutant non-small cell lung cancer (NSCLC) fall sho...
Reflex precision oncology consultation to increase comprehensive genomic profiling rates in non-small cell lung cancer.
e20657 Background: Targeted therapies have transformed the treatment landscape for advanced non-small-cell lung cancer (NSCLC). Comprehensive genomic prof...
Impact of race, gender and socioeconomic status on Ewing sarcoma survival over two decades.
e23514 Background: Ewing’s Sarcoma is a rare malignant tumor of the bone or soft tissue often afflicting children and young adults. While several studies...
Use of AlphaFold 2 to predict stabilizing mutations for the R337H variant in the tetramerization domain of TP53.
e15118 Background: TP53 mutations occur in nearly 50% of human cancers, profoundly affecting protein structure and function. The R337H variant is the most...
Optimizing tarlatamab therapy for relapsed small cell lung cancer: Biomarker identification and addressing treatment delivery disparity.
e23106 Background: SCLC is a highly aggressive malignancy with limited treatment options and high relapse rates. Tarlatamab, a BiTE targeting DLL3, demons...
Clinicopathological features and risk factors of type 1 and type 2 endometrial cancer: A retrospective single-centre analysis.
e17616 Background: Endometrial cancer (EC) is the most common gynecological malignancy globally and the fourth most prevalent cancer among females. EC is...
Diversities and disparities in endometrial carcinoma (EC): Clinical pathological features and outcomes from indigenous populations—A French multicentric retrospective study.
e13803 Background: Disparities in cancer care access remain significant. Cancer epidemiology in French overseas territories (FOT) differs from mainland Fr...
Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
1079 Background: Tumors develop resistance following 1L endocrine therapy (ET) + CDK4/6i in ER+/HER2- mBC. Elacestrant (Ela) significantly improved PFS vs...
Tobacco smoking as a risk for cutaneous squamous cell carcinoma in skin of color.
9589 Background: Ultraviolet radiation (UVR) along with immunosuppression, tobacco smoking and age are the major risk factor cutaneous squamous cell carci...
Real world outcomes of venetoclax combined with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: Insights from a tertiary care centre in Pakistan.
e18532 Background: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are hematologic malignancies associated with dismal outcomes in elderly...
The prevalence and outcomes of hypercalcemia in Black American patients hospitalized with lung cancer: Findings from the Nationwide Inpatient Sample.
e20537 Background: Hypercalcemia is a common complication in cancer patients, often associated with significant morbidity. African American lung cancer pa...
Artificial intelligence for immunotherapy response assessment in lung cancer using PET-CT reports.
8577 Background: Accurate and timely assessment of immunotherapy response is vital for optimizing lung cancer management. This study evaluates the efficac...
The efficacy of molecule-matched treatment on hyperprogressive disease after immunotherapy: A retrospective study from the Molecular Tumor Board registry.
e15187 Background: Hyperprogressive disease (HPD) is a severe adverse event following immunotherapy, often resulting in rapid patient deterioration and de...
Effect of G-CSF primary prophylaxis on prevention of severe neutropenia in FOLFIRINOX therapy: A systematic review and a meta-analysis.
e24086 Background: While FOLFIRINOX (leucovorin, fluorouracil, irinotecan and oxaliplatin) has been well established for gastrointestinal cancer treatment...
A meta-analysis analyzing the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in previously treated patients with non-small cell lung cancer (NSCLC).
e20674 Background: Dato-DXd is an antibody-drug conjugate with a TROP2-directed monoclonal antibody. Recent trials have demonstrated promising efficacy fo...